Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$571.00K$571.00K+0.7% vs Q3 2019 Net Income-$7.76M-$7.76MN/M vs Q3 2019 EPS Diluted-$0.05-$0.05N/M vs Q3 2019 Gross Profit$469,000+3.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,847,000N/M Free Cash Flowderived-$4,871,000N/M Margins · derivedGross margin82.1%+2.2 pt vs Q3 2019
Operating margin-1177.8%+307.6 pt vs Q3 2019
Net margin-1359.0%+1551.9 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 4, 2020 · 35 d after period end